Characteristics of Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Therapy with Canagliflozin

被引：0
|
作者：
Martin, Silas C.
Henk, Henry J.
Chow, Wing
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1181-P
引用
收藏
页码：A307 / A307
页数：1
相关论文
共 50 条
  • [41] Gut microbiota influence in type 2 diabetes mellitus (T2DM)
    A. L. Cunningham
    J. W. Stephens
    D. A. Harris
    [J]. Gut Pathogens, 13
  • [42] Pregnancy outcomes in women with Type 2 diabetes mellitus (T2DM)
    Tan, Z.
    Pang, W. H.
    Todd, D.
    Halliday, M.
    Gill, F.
    Rhoads, M.
    Sathiskumar, P.
    Gallagher, A.
    de Chazal, R.
    Lawrence, I. G.
    [J]. DIABETIC MEDICINE, 2008, 25
  • [43] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [44] Gut microbiota influence in type 2 diabetes mellitus (T2DM)
    Cunningham, A. L.
    Stephens, J. W.
    Harris, D. A.
    [J]. GUT PATHOGENS, 2021, 13 (01)
  • [45] Graft of Microencapsulated Sertoli Cells for the Cell Therapy of Type 2 Diabetes Mellitus (T2DM)
    Luca, Giovanni
    Mancuso, Francesca
    Calvitti, Mario
    Arato, Iva
    Falabella, Giulia
    Bobo, Mariella
    Beccetti, Ennio
    Calafiore, Riccardo
    [J]. TRANSPLANTATION, 2013, 96 (06) : S116 - S116
  • [46] Long-term Efficacy and Safety of Canagliflozin (CANA) in Older Patients with Type 2 Diabetes Mellitus (T2DM) Over 104 Weeks
    Bode, Bruce
    Stenlof, Kaj
    Harris, Stewart
    Sullivan, Daniel
    Fung, Albert
    Usiskin, Keith
    [J]. DIABETES, 2014, 63 : A71 - A71
  • [47] Real-World (RW) Glycemic Control and Medication Adherence among Patients with Type 2 Diabetes Mellitus (T2DM) Initiated on Canagliflozin
    Jain, Rahul
    Cai, Jennifer
    Fu, An-Chen
    Chow, Wing
    Tan, Hiangkiat
    [J]. DIABETES, 2016, 65 : A304 - A305
  • [48] Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy
    Fulcher, Greg
    Matthews, David
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    Weiss, Robert
    Rosenstock, Julio
    Capuano, George
    Desai, Mehul
    Shaw, Wayne
    Vercruysse, Frank
    Meininger, Gary
    Neal, Bruce
    [J]. DIABETES, 2013, 62 : A292 - A292
  • [49] SHORT-TERM ECONOMIC AND CLINICAL OUTCOMES OF CANAGLIFLOZIN COMPARED TO SITAGLIPTIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS (T2DM)
    Lopez, J. M.
    Martin, S.
    Ektare, V
    Patel, D.
    Rupnow, M. F.
    Botteman, M. F.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A251 - A251
  • [50] Assessing MicroRNA-375 Levels in Type 2 Diabetes Mellitus (T2DM) Patients and Their First-Degree Relatives with T2DM
    Wu, Xu
    Li, Yashan
    Man, Baohua
    Li, Dexuan
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 1445 - 1451
12345